Skip to content

Cash ratio at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
0.4×-0.3×
Merck & Co. logo
Merck & Co.MRK
0.2×-0.1×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
+1.8×
UroGen Pharma logo
UroGen PharmaURGN
2.2×-0.3×
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
2.4×-0.1×
CG Oncology logo
CG OncologyCGON
-0.9×

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Calculated from Aura Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s cash ratio?
Aura Biosciences, Inc. (AURA) reported cash ratio of 5.1× in Q1 2026.
How has Aura Biosciences, Inc.'s cash ratio changed year-over-year?
Aura Biosciences, Inc.'s cash ratio increased by 61.5% year-over-year, from 3.1× to 5.1×.
What is the long-term trend for Aura Biosciences, Inc.'s cash ratio?
Over 5 years (2020 to 2025), Aura Biosciences, Inc.'s cash ratio has grown at a -13.1% compound annual growth rate (CAGR), from 6.5× to 3.2×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.